ARTICLE | Company News

Gilead’s Goldfinch deal signals renewed optimism in kidney therapies

May 8, 2019 2:31 PM UTC

In the latest sign of that the kidney is regaining attention for drug developers, Gilead has tapped Goldfinch's drug discovery tools to co-develop therapies for diabetic kidney disease and orphan kidney diseases.

Goldfinch Biopharma Inc. (Cambridge, Mass.) CEO Tony Johnson told BioCentury that after a string of past failures among pharma companies developing kidney therapies, the space is now opening up with a better regulatory environment and greater understanding of kidney disease. ...